Earnings Call
Aug 5, 2026
Q2 FY2026
EPS Estimate
4.35
EPS Actual
4.75
Post-Earnings Close
$317.22
Earnings Reaction
+3.6%
Cencora's fiscal second quarter results came in below Street expectations on revenue but above on EPS, with adjusted diluted EPS of $4.75 representing 7.5% growth year-over-year against an estimate of $4.35. Revenue of $78.4 billion grew 4% but fell well short of the ~$84.3 billion consensus, driven by a confluence of factors that management characterized as largely transitory or already embedded in the model. The headline revenue miss is real but arguably less meaningful than it appears: the primary culprits, IRA-driven manufacturer WAC price reductions, faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, and slower GLP-1 volume growth, are predominantly low-margin or zero-margin revenue streams whose loss has limited operating income consequence. Management's decision to raise full-year EPS guidance to $17.65, $17.90 (from $17.45, $17.75) while simultaneously cutting revenue growth guidance to 4%, 6% (from 7%, 9%) underscores this dynamic and reflects the margin-accretive mix shift underway across the business.
Report generated on Aug 4, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full COR analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.